Acute Myeloid Leukemia
Conditions
Interventions
High-Risk AML Group:None
Sponsors
The Second Affiliated Hospital of Army Medical University, Xinqiao Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with acute myeloid leukemia (AML) at our center (with a risk assessment classified as high-risk AML (refer to "Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Non-Acute Promyelocytic Leukemia) in China (2023 Edition)" Chinese Journal of Hematology, 2023, 44(9): 705-712.), for details on the risk assessment of AML patients, see Figure 2), are candidates for transplantation, have a qualified donor, and are planned to undergo hematopoietic stem cell transplantation after two courses of chemotherapy, with no gender restrictions, and aged between 18-50 years; (2) A KPS score >60, with an expected survival of more than 6 months; (3) No severe systemic organ dysfunction: ? Creatinine 55%; ? Hemoglobin >9g/dL, Bilirubin <2.0mg/dl; (4) No contraindications for hematopoietic stem cell transplantation; (5) Willing to participate in this study and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Active bleeding caused by drug or thrombocytopenia; (2) Pregnant or lactating women; (3) Severe heart, kidney, or liver dysfunction; (4) Patients with other malignancies requiring treatment; (5) Clinical symptoms of brain dysfunction or severe mental disorders that prevent understanding or following the study protocol; (6) Patients who cannot ensure the completion of the required treatment plan and follow-up observations; (7) Patients with severe acute allergic reactions; (8) Clinically uncontrolled active infection; (9) Insufficient residual bone marrow blood samples of less than 3ml after routine bone marrow puncture for the subject; (10) Subjects deemed unsuitable for clinical trials for other reasons by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Single-Cell Transcriptome Sequencing;Single-Cell Transcriptomics;Single-Cell Metabolomics; | — |
Countries
China
Contacts
Public ContactXi Zhang
The Second Affiliated Hospital of Army Medical University, Xinqiao Hospital
Outcome results
None listed